Riboxin 200 mg is a medicinal product containing inosine, a purine nucleoside involved in cellular metabolic processes. It has traditionally been used as a metabolic agent in supportive or combination therapy for certain cardiovascular and hepatic conditions. Each tablet provides 200 mg of inosine. Riboxin has been used to support myocardial metabolic processes and cellular energy metabolism, particularly as part of broader physician-directed treatment. Because indications and regulatory status for inosine-containing medicines vary by country, Riboxin should be used according to the specific product leaflet and healthcare professional guidance. Key Features Contains inosine 200 mg per tablet Traditionally classified as a metabolic agent Used as part of combination therapy in certain cardiovascular conditions Supports myocardial metabolic processes Has been used in supportive therapy for certain liver conditions Oral tablet formulation 50 tablets per package Active Ingredient Each Tablet Contains: Inosine (Riboxin) – 200 mg Inosine is a naturally occurring purine nucleoside involved in biochemical pathways associated with cellular metabolism. Traditional Indications Depending on the manufacturer and country-specific prescribing information, Riboxin has traditionally been included in complex therapy for conditions such as: Coronary heart disease Recovery following myocardial infarction Angina Certain cardiac arrhythmias Cardiomyopathies Myocardial metabolic disturbances Certain liver disorders, including hepatitis and cirrhosis Fatty liver degeneration Certain situations involving increased metabolic demands Some regional product information also describes additional specialized uses. These should only be included when supported by the specific manufacturer's package insert for the product being sold. Cardiovascular Use Riboxin has historically been used as an adjunctive metabolic treatment in cardiovascular medicine. Its proposed role relates to myocardial metabolism and cellular biochemical processes rather than directly lowering blood pressure or functioning as a conventional antianginal or antiarrhythmic drug. It should not replace established cardiovascular medications prescribed for coronary artery disease, arrhythmias, heart failure, or other cardiac conditions. Directions for Use Dosage should follow the manufacturer's package instructions or healthcare professional's recommendation, as dosing schedules can differ between Riboxin products and markets. Tablets are generally taken orally, typically before meals, with sufficient water. Do not exceed the recommended dose. Product Details Product: RiboxinGeneric / Active Ingredient: InosineStrength: 200 mg per TabletDosage Form: TabletsPack Size: 50 TabletsDrug Category: Metabolic AgentAdministration: Oral Important Information Riboxin can influence uric acid metabolism. Particular caution is therefore appropriate in individuals with elevated uric acid levels. Do Not Use / Consult a Healthcare Professional Before Use If: You have gout You have hyperuricemia (elevated uric acid) You have significant kidney impairment You are allergic to inosine or another ingredient in the product You are pregnant or breastfeeding You take prescription medications for cardiovascular or metabolic conditions Periodic monitoring of uric acid levels in the blood and urine may be appropriate during treatment, particularly with prolonged use. Possible Side Effects Possible adverse effects may include: Increased blood uric acid Exacerbation of gout in susceptible individuals Itching Skin redness Other hypersensitivity reactions Discontinue use and seek medical advice if a significant allergic reaction or other unexpected adverse effect develops. General Disclaimer Riboxin is a medicinal product and should be used according to its package leaflet and professional medical guidance. It is not a substitute for established treatment of cardiovascular, hepatic, or other medical conditions.
Related
Related
Related
Related